Compare New York Times Co (NYT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs BIO-TECHNE Corp — how do they compare? New York Times Co trades at $63.73 (market cap $10.45B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: New York Times Co and BIO-TECHNE Corp are close in size by market cap, and New York Times Co pays the higher dividend (1.42%). Which is the better fit depends on your goals.
| NYT | TECH | |
|---|---|---|
Market Cap | $10.45B | $11.24B |
Sector | Media | Health |
52-Week High | $85.86 | $72.29 |
52-Week Low | $54.66 | $43.31 |
Enterprise Value | $9.85B | $11.32B |
Dividend Yield | 1.42% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times (NYT) stock trades at $63.54, down 1.9% recently, with a bearish technical signal from moving averages but neutral oscillators. Fundamentally, the company shows strong profitability with a 13.19% net income margin and consistent earnings beats, including Q2 2026 EPS of $0.69 versus $0.663 expected. Revenue growth is steady, reaching $2.82B in 2025, though digital subscriber additions have moderated, contributing to near-term stock weakness.
Outlook remains mixed; analyst consensus targets $77.50 with 29% buy ratings, but slower subscriber growth and high valuation (P/E 26.48) pose risks. Opportunities include digital expansion and pricing power, while risks involve competition and economic sensitivity. The stock's current level near support at $63 may attract value-oriented investors if fundamentals hold.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
